Acadia Pharmaceuticals(ACAD)

SAN DIEGO, CAPharmaceutical1 H-1B visas (FY2023)

Focus: Acadia Pharmaceuticals is a public specialty pharma company focused on neurology small molecules, generating $726M in FY2025 revenue with dominant market position through its flagship antipsychotic NUPLAZID. The company operates as a peak-stage player in rare neurological and psychiatric indications.

Neurology

Profile data last refreshed 9h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

40+1 this month

Stable — net +1 jobs in 30d

29 added, 28 removed. Backfill posture.

Should You Work at Acadia Pharmaceuticals?

AI assessment

Acadia offers commercial growth and pipeline depth for specialists seeking stable neurology experience, but extreme revenue concentration and burn rate require confidence in Phase 3 program success.

Why Work Here

Strong revenue base ($726M FY2025, +40% YoY) and improving profitability trajectory provides stability and growth opportunity in a commercial-heavy hiring environment.

Data completeness

7/9 — Strong

Company HealthStrong

Pipeline

Late-stage

3 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$726M

Key Products

NUPLAZID

Parkinson's disease psychosis hallucinations and delusions

$596M Part D

Peak

Help build intelligence for Acadia Pharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Commercial and Medical Affairs are actively hiring (18 combined roles), signaling expansion beyond the lead product and international market development.

Solid pipeline depth with 8 Phase 3 programs (trofinetide/Rett, ACP-204/Lewy Body, carbetocin/Prader-Willi) and 10 Phase 2 programs offers mid-career scientists meaningful drug development exposure.

Watch Out For

Extreme revenue concentration (97% from NUPLAZID) creates existential risk; NUPLAZID faces patent cliff in 2037-2039, leaving <11 years to mature pipeline replacements.
Negative net income ($-61M FY2025, $-216M FY2024) despite revenue growth signals profitability challenges; cash position ($189M) may not survive sustained losses if pipeline falters.

Generated by Claude from Acadia Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Core revenue driver generating 97% of company sales; serotonin 5-HT2A inverse agonist with robust post-marketing pharmacovigilance (27 active trials).

DAYBUE

Rett syndrome

$19M Part D

Peak16.2yr

Orphan-approved treatment in early commercial phase with 19-year LOE window; Phase 3 program active in parent indication suggests label expansion potential.

NUPLAZID

Secondary indication (Parkinson's disease psychosis)

Peak12.3yr

Additional patent protection on pimavanserin dosing regimen; multiple LOE dates reflect compound's diversified patent estate.

PIMAVANSERIN

Hallucinations and delusions associated with Parkinson's disease psychosis

Post-LOE

Generic/ANDA-stage version post-LOE; reflects competitive erosion of brand market share as exclusivity expires.

DAYBUE STIX

Rett syndrome

Launch16.2yr

Novel formulation variant recently launched; line extension supports patient convenience and potential market segmentation within Rett population.

PIMAVANSERIN

Hallucinations and delusions associated with Parkinson's disease psychosis

Post-LOE

Duplicate ANDA entry reflecting multiple generic pathways; indicates aggressive market genericization post-LOE.

Pipeline & Clinical Trials

Real-world non-interventional

Parkinson Disease Psychosis

N/A

Real-world, non-interventional

Parkinson Disease Psychosis

N/A

Clinical Trials (1)

NCT03152292The INSYTE (Management of Parkinson's Disease Psychosis in Actual Practice) Study

N/A

Support program

Knee Arthropathy

N/A

Clinical Trials (1)

NCT06575621Knee-hip Surgery Wait-list Support Program

N/A

Virtual reality guided motor rehabilitation

Stroke Acute

N/A

Clinical Trials (1)

NCT06864741Virtual Reality Rehabilitation for Stroke Patients in the Hospital and at Home.

N/A

Observation of minor phenomena

Parkinson Disease

N/A

Clinical Trials (1)

NCT05240339Characterization and Progression of Minor Phenomena in Parkinson's Disease (PD)

N/A

ACP-044

Osteoarthritis Pain

Phase 2

Clinical Trials (2)

NCT04855240Evaluate the Efficacy and Safety of ACP-044 for the Treatment of Acute Postoperative Pain Following Bunionectomy

Phase 2

NCT05008835Evaluate the Efficacy and Safety of ACP-044 in Subjects With Pain Associated With Osteoarthritis of the Knee

ACP-103

Hallucinations

Phase 2

Clinical Trials (5)

NCT00477672A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

Phase 3

NCT00658567A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

ACP-103

Schizophrenia

Phase 2

Clinical Trials (1)

NCT00361166Antipsychotic and Motor Effects of ACP-103 When Administered in Combination With Haloperidol and Risperidone

Phase 2

ACP-211

Major Depressive Disorder (MDD)

Phase 2

Clinical Trials (1)

NCT07284667ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response

Phase 2

ACP-104

Schizophrenia

Phase 2

Clinical Trials (2)

NCT00490516ACP-104 in Acutely Psychotic Subjects With Schizophrenia

Phase 2

NCT00628420Safety Study of ACP-104: To Demonstrate the Safety, Tolerability, and Pharmacokinetics

Phase 1

carbetocin

Hyperphagia in Prader-Willi Syndrome

Phase 3

Clinical Trials (2)

NCT06420297OLE Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome

Phase 3

NCT06173531Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome

ACP-204

Lewy Body Dementia Psychosis

Phase 3

Clinical Trials (4)

NCT07095465Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis

Phase 3

NCT06194799ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study

Phase 3

trofinetide

Rett Syndrome

Phase 3

Clinical Trials (4)

NCT04776746Open-Label Extension Study of Trofinetide for Rett Syndrome

Phase 3

NCT04279314Open-Label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome

Phase 3

pimavanserin

Parkinson's Disease Psychosis

Phase 4

Clinical Trials (5)

NCT05357612Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases

Phase 4

NCT04292223Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis

L. helveticus R0052 and B. longum R0175

Attention Deficit Hyperactivity Disorder

Phase 4

Clinical Trials (1)

NCT02545634Effects of a Probiotic Supplement on Symptoms of Attention Deficit Hyperactivity Disorder and Anxiety in Children

Phase 4

probiotics

Attention Deficit Hyperactivity Disorder

Phase 4

Clinical Trials (1)

NCT02035878Probiotics and the Microbiome: Clinical Intervention Trial for Anxiety and Depression

Phase 2

Interview Prep Quick Facts

Portfolio: 6 approved products, 54 clinical trials

Top TAs: Neurology, Rare Diseases

H-1B (2023): 1 approval

Publications: 37 in PubMed

SEC Filings: 2 available

Open Roles: 40 active jobs

Portfolio Health

Launch1 (17%)

Peak3 (50%)

Post-LOE2 (33%)

6 total products

Therapeutic Area Focus

Neurology

4 marketed34 pipeline

Rare Diseases

2 marketed4 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$726M40%

R&D Spend

$352M(48%)3%

Net Income

-$61M

Hiring Trend

Stable

Open Roles

Added

-7

Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Research Publications(10)

Recent peer-reviewed publications with author affiliations at this company

Rett syndrome and real-world treatment patterns of trofinetide in the United States.

Journal of medical economics

2026

PMID:42287113

Consistent unmet needs and fragmented care in Rett syndrome: insights from a multi-country European caregiver study.

NCT00550238A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

Phase 3

NCT06159673ACP-204 in Adults With Alzheimer's Disease Psychosis

Phase 2/3

NCT04181723Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™)

Phase 3

NCT04809116Pimavanserin for Insomnia in Veterans With Posttraumatic Stress Disorder: Proof of Concept

Phase 4

Orphanet journal of rare diseases

Showing 5 of 10 publications

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Acadia Pharmaceuticals(ACAD)

Should You Work at Acadia Pharmaceuticals?

Why Work Here

Key Products

Watch Out For

Products & Portfolio (2)

Key Products by Revenue

Other Products (1)

Pipeline & Clinical Trials

Recent News · Acadia Pharmaceuticals(10)

Open Jobs (40)

Sr. Talent Acquisition Partner

Director, Consumer Marketing

Sr. Director, Regulatory Affairs, Technology & Transformation

Sr. Manager Quality Audit and Compliance

Executive Director, People Business Partnership

Neuroscience Regional Sales Manager - Pacific

Associate Director, Regulatory Operations

Senior Medical Safety Scientist

Associate Director, Clinical Data Integration & AI Programming

Sr. Manager, IT - Commercial Veeva Platforms

Associate Director, HCP Marketing (Health Systems & Long-Term Care)

Paralegal, Contracts

Senior Administrative Assistant

Executive Director, Tax

Director, Content Development

Senior Director / Executive Director, Clinical Development

Director, GCP Quality Assurance

Director, AI Engineering

Director, Clinical Development

Financials (FY2025)

Hiring Trend

Visa Sponsorship

Research Publications(10)